NEUROGLYCOPENIA: GENOTYPE-PHENOTYPE CORRELATION
NEUROGLYCOPENIA: GENOTYPE-PHENOTYPE CORRELATION
批准号:
6798746
负责人:
DARRYL C DE VIVO
金额:
$46.8万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 2008-08-31
关键词:
Xenopus oocyteapoptosisbiopsyclinical researchdevelopmental disease /disorderdevelopmental neurobiologydiazoxidedietary carbohydratesdietary lipiddietary supplementsgene mutationgene targetinggenetic polymorphismgenetically modified animalsgenotypeglucagonglucose tolerance testglucose transporterhuman subjecthyperglycemialaboratory mouselongitudinal human studyneuropathologynutrition related tagpathologic processphenotypepoint mutationprotein structure functionsite directed mutagenesis
中文摘要
描述(由申请方提供):葡萄糖转运蛋白I型(Glut 1)缺乏时(GlutIDS,OMIM 606777),会导致慢性神经性低血糖症和发育性脑病。这种缺陷是由GLUT 1单倍不足引起的,作为一种常染色体显性遗传性状遗传。该研究项目的长期目标是提高对发病机制的理解,提高对表型表现的认识,以及更好地治疗神经发育综合征。提出了四个具体目标来实现这些长期目标:(1)扩展我们对与GLUT 1基因突变相关的GlutlDS表型的理解;(2)将基因型致病性与表型严重性相关联;(3)在动物模型中复制人类疾病;(4)探索GlutlDS患者的替代治疗选择。研究设计和方法的开发旨在增加患者招募;通过多学科方法评估表型变异性;并随时间推移对患者进行系列评价,以评估发育期间的表型持久性和性别对临床表达的影响。通过评估突变的性质以及由这些突变引起的动力学和结构-功能扰动,将表型与基因型相关联。非洲爪蟾卵母细胞表达系统用于评估与错义突变相关的功能障碍。将在GlutIDS人群中确定GLUT 1多态性,并与对照人群中存在/不存在相似多态性进行比较。将对转基因反义小鼠模型和基因靶向同源重组敲除小鼠模型进行临床和神经病理学检查,以获得局部脑损伤和神经元凋亡的证据。重点将放在确定受疾病影响最严重的细胞类型上。细胞功能障碍和细胞凋亡将通过来自突变小鼠模型的神经元和神经胶质培养物的体外研究进行评估。将在小鼠模型中探索治疗机会,并将其应用于患者人群,评估生酮饮食和碳水化合物饮食的相对获益,以及使用生玉米淀粉补充剂和二氮嗪治疗持续高血糖症的优势。将评价5小时口服葡萄糖耐量试验,作为测量与一过性高血糖症相关的临床、神经心理学和心电图变化的可能诊断工具。
英文摘要
DESCRIPTION (provided by applicant): Glucose transporter protein Type I (Glut1), when deficient (GlutlDS, OMIM 606777), causes chronic neuroglycopenia and developmental encephalopathy. The deficiency results from GLUT1 haploinsufficiency, genetically transmitted as an autosomal dominant trait. The long-term objectives of this research project are improved understanding of the pathogenesis, increased awareness of the phenotypic presentations, and better treatment of the neurodevelopmental syndrome. Four specific aims are proposed to achieve these long-term objectives: (1) To expand our understanding of the GlutlDS phenotypes associated with GLUT1 gene mutations; (2) To correlate genotypic pathogenicity with phenotypic severity; (3) To replicate the human disease in an animal model; (4) To explore alternative treatment options for patients with GlutlDS. The research design and methods have been developed to increase recruitment of patients; to assess phenotypic variability by multi-disciplinary methods; and to serially evaluate patients over time to assess the phenotypic durability during development and the influences of gender on clinical expression. The phenotype will be correlated with the genotype by assessing the nature of the mutation and the kinetic and structure-function perturbations that result from these mutations. The Xenopus oocyte expression system is used to evaluate functional disturbances related to missense mutations. GLUT1 polymorphisms will be determined in the GlutlDS population and compared to the presence/absence of similar polymorphisms in a control population. A transgenic antisense mouse model and gene targeted homologous recombination knock-out mouse model will be examined clinically and neuropathologically for evidence of regional brain injury and neuronal apoptosis. Emphasis will be placed on establishing the cellular types most affected by the disease. Cellular dysfunction and apoptosis will be assessed by the in vitro study of neuronal and glial cultures derived from the mutant mouse models. Treatment opportunities will be explored in the mouse models and applied to the patient population assessing the relative benefits of a ketogenic diet and a carbohydrate diet, and the advantages of sustained hyperglycemia using uncooked cornstarch supplements and diazoxide. A 5-hour oral glucose tolerance test will be evaluated as a possible diagnostic tool measuring clinical, neuropsychological and electrographic changes associated with transient hyperglycemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project #1 - MELAS-3243: Natural history, functional outcome measures, and predic
-
批准号:8741705
-
项目类别:
-
资助金额:$46.24万
-
财政年份:2014
-
负责人:DARRYL C DE VIVO
-
依托单位:
CLINICAL SYNDROMES & MT DNA POINT MUTATIONS
-
批准号:7547768
-
项目类别:
-
资助金额:$42.02万
-
财政年份:2007
-
负责人:DARRYL C DE VIVO
-
依托单位:
CLINICAL SYNDROMES ASSOCIATED WITH MTDNA POINT MUTATIONS
-
批准号:7205884
-
项目类别:
-
资助金额:$2.23万
-
财政年份:2005
-
负责人:DARRYL C DE VIVO
-
依托单位:
NEUROGLYCOPENIA: GENOTYPE-PHENOTYPE CORRELATIONS
-
批准号:7205892
-
项目类别:
-
资助金额:$1.55万
-
财政年份:2005
-
负责人:DARRYL C DE VIVO
-
依托单位:
INVESTIGATION OF CLINICAL SYNDROMES ASSOCIATED WITH MTDNA POINT MUTATIONS
-
批准号:7205905
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2005
-
负责人:DARRYL C DE VIVO
-
依托单位:
CLINICAL SYNDROMES ASSOCIATED WITH mt DNA POINT MUTATION
-
批准号:6859043
-
项目类别:
-
资助金额:$83.43万
-
财政年份:2004
-
负责人:DARRYL C DE VIVO
-
依托单位:
Neuroglycopenia: Genotype-Phenotype Correlations
-
批准号:7045005
-
项目类别:
-
资助金额:$2.03万
-
财政年份:2003
-
负责人:DARRYL C DE VIVO
-
依托单位:
Investigation of Clinical Syndromes Associated with mtDNA Point Mutations
-
批准号:7045018
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2003
-
负责人:DARRYL C DE VIVO
-
依托单位:
Clinical Syndromes Associated With mtDNA Point Mutations
-
批准号:7044996
-
项目类别:
-
资助金额:$1.42万
-
财政年份:2003
-
负责人:DARRYL C DE VIVO
-
依托单位:
NEUROGLYCOPENIA GENOTYPE PHENOTYPE CORRELATIONS
-
批准号:6567844
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2001
-
负责人:DARRYL C DE VIVO
-
依托单位:
CLINICAL SYNDROMES ASSOCIATED WITH MTDNA POINT MUTATIONS
-
批准号:6567746
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2001
-
负责人:DARRYL C DE VIVO
-
依托单位:
NEUROGLYCOPENIA GENOTYPE PHENOTYPE CORRELATIONS
-
批准号:6468581
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2000
-
负责人:DARRYL C DE VIVO
-
依托单位:
CLINICAL SYNDROMES ASSOCIATED WITH MTDNA POINT MUTATIONS
-
批准号:6468486
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2000
-
负责人:DARRYL C DE VIVO
-
依托单位:
STROKE AND NEUROLOGICAL ASPECTS OF SICKLE CELL DISEASES
-
批准号:6109603
-
项目类别:
-
资助金额:$13.55万
-
财政年份:1999
-
负责人:DARRYL C DE VIVO
-
依托单位:
NEUROLOGICAL COMPLICATIONS OF SICKLE CELL DISEASE
-
批准号:6117616
-
项目类别:
-
资助金额:$2.21万
-
财政年份:1998
-
负责人:DARRYL C DE VIVO
-
依托单位:
NEUROGLYCOPENIA: GENOTYPE-PHENOTYPE CORRELATION
-
批准号:6678316
-
项目类别:
-
资助金额:$45.46万
-
财政年份:1998
-
负责人:DARRYL C DE VIVO
-
依托单位:
CLINICAL SYNDROMES ASSOCIATED WITH MTDNA POINT MUTATIONS
-
批准号:6220037
-
项目类别:
-
资助金额:$0.04万
-
财政年份:1998
-
负责人:DARRYL C DE VIVO
-
依托单位:
STROKE AND NEUROLOGICAL ASPECTS OF SICKLE CELL DISEASES
-
批准号:6272638
-
项目类别:
-
资助金额:$13.41万
-
财政年份:1998
-
负责人:DARRYL C DE VIVO
-
依托单位:
NEUROGLYCOPENIA: GENOTYPE-PHENOTYPE CORRELATION
-
批准号:7111053
-
项目类别:
-
资助金额:$48.42万
-
财政年份:1998
-
负责人:DARRYL C DE VIVO
-
依托单位:
NEUROGLYCOPENIA--GENOTYPE/PHENOTYPE CORRELATION
-
批准号:6188132
-
项目类别:
-
资助金额:$40.0万
-
财政年份:1998
-
负责人:DARRYL C DE VIVO
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: